Review Article
Dichloroacetate (DCA) and Cancer: An Overview towards Clinical Applications
Table 1
List of reports suggesting beneficial effect of DCA and chemotherapy coadministration in several types of cancers.
| Tumour entity | Model system | Chemotherapy drug coadministered with DCA | Mechanism of action | Outcome | References |
| Lung cancer | A549-H1975 cell lines/xenograft model | Paclitaxel | Autophagy inhibition | Efficacious cancer chemotherapy sensitization | [32] | Hepatocarcinoma | HepG2 cell line | Doxorubicin | Antioxidant defence disruption | Increased cellular damage by oxidative stress induction | [33] | Lung cancer | A549 cell line | Paclitaxel | Increased chemosensitivity through PDK2 inhibition | Paclitaxel resistance overcome | [34] | Bladder cancer | HTB-9, HT-1376, HTB-5, HTB-4 cell lines/xenograft model | Cisplatin | Increased chemosensitivity through PDK4 inhibition | Increased cell death of cancer cells and potential therapeutic advantage | [35] | Hepatocarcinoma | Sphere cultures from HepaRG and BC2 cell lines | Cisplatin, sorafenib | Increased chemosensitivity through PDK4 inhibition | Improved therapeutic effect of chemotherapy by mitochondrial activity restoration | [36] |
|
|